The US National Institutes of Health (NIH) has awarded a grant of up to $4.6m to University of Sydney spinout Kinoxis Therapeutics to support the development of a potential treatment for opioid withdrawal.
The money, awarded under the NIH Helping to End Addiction Long-term (HEAL) initiative, will support pre-clinical and clinical development of the company’s small molecule therapeutic drug candidate KNX100.
Go deeper with GlobalData
KNX100, discovered by researchers at the University of Sydney, is being developed for a range of substance use disorders, including opioid use disorder.
Kinoxis says the compound has demonstrated potent anti-addictive properties in several pre-clinical models.
Kinoxis Therapeutics CEO Hugh Alsop said: “This award provides the opportunity for Kinoxis to augment and accelerate the development of our lead compound, KNX100, into human clinical studies.
“The award is recognition by NIDA and the NIH of KNX100’s potential to successfully manage opioid withdrawal symptoms and help curb the opioid crisis.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe funding forms part of 375 grants, contracts and cooperative agreements, across 41 states through the NIH HEAL initiative.
Health and Huma Services (HHS) Secretary Alex Azar said: “President Trump’s approach to the opioid crisis and HHS’s strategy have both been based on the best science we have.
“We have effective tools, such as medication-assisted treatment but we still need better ways to treat opioid addiction and manage pain in an effective, personalized way.”
In 2016, an estimated 50 million US adults suffered from chronic pain. In 2018, an estimated 10.3 million people 12 years and older in the US misused opioids.
Kinoxis is developing a range of therapeutic small molecule compounds to treat substance use disorders and other central nervous system disorders. The company has licensed the compounds from the University of Sydney.
